Cathepsin C is a tissue-specific regulator of squamous carcinogenesis

Genes and Development

Volumn 27, Issue 19, 2013, Pages 2086-2098

  Ruffell, Brian ^a,g   Affara, Nesrine I ^a   Cottone, Lucia ^a,b   Junankar, Simon ^a   Johansson, Magnus ^a   DeNardo, David G ^a   Korets, Lidiya ^a   Reinheckel, Thomas ^c   Sloane, Bonnie F ^d   Bogyo, Mathew ^e   Coussens, Lisa M ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF FREIBURG   (Germany)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Cathepsin C; Dipeptidyl peptidase I; Fibroblasts; Leukocytes; Skin

Indexed keywords

DIPEPTIDYL PEPTIDASE I; PLATELET DERIVED GROWTH FACTOR A; SMOOTH MUSCLE ACTIN; CATHEPSIN B; CHYMASE; PANCREATIC ELASTASE;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CARCINOGENESIS; CELL INFILTRATION; ENZYME ACTIVITY; FIBROBLAST; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TISSUE SPECIFICITY; TUMOR MICROENVIRONMENT; ANIMAL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CATHEPSIN B; CATHEPSIN C; CELL LINE, TUMOR; CHYMASES; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC ELASTASE; SKIN NEOPLASMS;

EID: 84885337942     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.224899.113     Document Type: Article

References (71)

1. Adkison AM, Raptis SZ, Kelley DG, Pham CT. 2002. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 109: 363-371.
2. Affara NI, Andreu P, Coussens LM. 2009. Delineating protease functions during cancer development. Methods Mol Biol 539: 1-32.
3. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al. 2010. FcRg activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17: 121-134.
4. Balkwill F, Charles KA, Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
5. Benavides F, Perez C, Blando J, Contreras O, Shen J, Coussens LM, Fischer SM, Kusewitt DF, Digiovanni J, Conti CJ. 2012. Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog 51: 352-361.
6. Boudreau F, Lussier CR, Mongrain S, Darsigny M, Drouin JL, Doyon G, Suh ER, Beaulieu JF, Rivard N, Perreault N. 2007. Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. FASEB J 21: 3853-3865.
7. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. 2013. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19: 57-64.
8. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. 1992. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278.
9. Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. 2002. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62: 4767-4772.
10. Coussens LM, Hanahan D, Arbeit JM. 1996. Genetic predisposition and parameters of malignant progression in K14- HPV16 transgenic mice. Am J Pathol 149: 1899-1917.
11. Coussens LM, Raymond WW, Bergers G, Laig-Webster M Behrendtsen O, Werb Z, Caughey GH, Hanahan D. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 13821397.
12. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387-2392.
13. Dahl SW, Halkier T, Lauritzen C, Dolenc I, Pedersen J, Turk V, Turk B. 2001. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry 40: 1671-1678.
14. + T cells. J Exp Med 197: 1017-1028.
15. + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91102.
16. DeNardo DG, Brennan D, Rexhapaj E, Ruffell B, Shiao S, Gallagher WM, Wadhani N, Kial SD, Junaid SA, Rugo HS, et al. 2011. Leukocyte complexity in breast cancer predicts overall survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
17. Dennemarker J, Lohmuller T, Mayerle J, Tacke M, Lerch MM, Coussens LM, Peters C, Reinheckel T. 2010. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene 29: 1611-1621.
18. De Visser KE, Korets LV, Coussens LM. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
19. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
20. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. 2010. Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kBdependent manner. Cancer Cell 17: 135-147.
21. Fonovic M, Bogyo M. 2007. Activity based probes for proteases: Applications to biomarker discovery, molecular imaging and drug screening. Curr Pharm Des 13: 253-261.
22. Frezzini C, Leao JC, Porter S. 2004. Cathepsin C involvement in the aetiology of Papillon-Lefevre syndrome. Int J Paediatr Dent 14: 466-467.
23. Gocheva V, Joyce JA. 2007. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6: 60-64.
24. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. 2006. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556.
25. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA. 2010. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241-255.
26. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. 2004. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23: 8486-8496.
27. Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA. 2012. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 61: 877-884.
28. Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, Joyce JA, Ploegh HL, Barrett TA, Weissleder R, Khazaie K. 2008. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS ONE 3: e2916.
29. Guay D, Beaulieu C, Percival MD. 2010. Therapeutic utility and medicinal chemistry of cathepsin C inhibitors. Curr Top Med Chem 10: 708-716.
30. Guy CT, Cardiff RD, Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961.
31. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, Domschke W, Lippert H, Peters C, Deussing J. 2000. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 106: 773-781.
32. Hart TC, Hart PS, Michalec MD, Zhang Y, Firatli E, Van Dyke TE, Stabholz A, Zlotogorski A, Shapira L, Soskolne WA. 2000. Haim-Munk syndrome and Papillon-Lefevre syndrome are allelic mutations in cathepsin C. J Med Genet 37: 88-94.
33. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9: 847-856.
34. Joyce JA, Hanahan D. 2004. Multiple roles for cysteine cathep-sins in cancer. Cell Cycle 3: 1516-1519.
35. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M, Hanahan D. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453.
36. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
37. Lilla JN, Werb Z. 2010. Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis. Dev Biol 337: 124-133.
38. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
39. Lin E, Gouon-Evans V, Nguyen A, Pollard J. 2002. The macro-phage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 7: 147-162.
40. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. 2006. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116: 1955-1962.
41. Lopez-Otin C, Matrisian LM. 2007. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
42. Mallen SCJ, Pham CT, Villalta SA, Caughey GH, Wolters PJ. 2004. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 113: 628-634.
43. Mason SD, Joyce JA. 2011. Proteolytic networks in cancer. Trends Cell Biol 21: 228-237.
44. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I, Babes L, Reinheckel T, Peters C, Zeiser R, et al. 2011. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol 6: 594-602.
45. Mohamed MM, Sloane BF. 2006. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-775.
46. Noack B, Gorgens H, Hoffmann T, Fanghanel J, Kocher T, Eickholz P, Schackert HK. 2004. Novel mutations in the cathepsin C gene in patients with pre-pubertal aggressive periodontitis and Papillon-Lefevre syndrome. J Dent Res 83: 368-370.
47. Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR. 2008. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 14: 45844592.
48. Palermo C, Joyce JA. 2008. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29: 22-28.
49. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. 1999. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274: 36505-36512.
50. Pham CT, Ley TJ. 1999. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci 96: 8627-8632.
51. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B, Ley TJ. 2004. Papillon-Lefevre syndrome: Correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol 173: 72777281.
52. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. 2004. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
53. Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, et al. 2013. Depletion of stromal cells expressing fibroblast activation protein-a from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 210: 1137-1151.
54. Rowan AD, Mason P, Mach L, Mort JS. 1992. Rat procathepsin B. Proteolytic processing to the mature form in vitro. J Biol Chem 267: 15993-15999.
55. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. 2012. Leukocyte composition in human breast cancer. Proc Natl Acad Sci 109: 2796-2801.
56. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119: 3613-3625.
57. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ. 1994. Molecular cloning of fibroblast activation protein a, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci 91: 5657-5661.
58. Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F, Stahl A, von Elverfeldt D, Becker AK, Bogyo M, et al. 2008. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem 389: 1067-1074.
59. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al. 2003. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92: 493-500.
60. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. 2011. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25: 2465-2479.
61. Tholen S, Biniossek ML, Gansz M, Gomez-Auli A, Bengsch F, Noel A, Kizhakkedathu JN, Boerries M, Busch H, Reinheckel T, et al. 2013. Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome. Mol Cell Proteomics 12: 611-625.
62. Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA. 2013. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 210: 1125-1135.
63. Turk B. 2006. Targeting proteases: Successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
64. Turk D, Guncar G, Podobnik M, Turk B. 1998. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol Chem 379: 137-147.
65. Turk D, Janjic V, Stern I, Podobnik M, Lamba D, Dahl SW, Lauritzen C, Pedersen J, Turk V, Turk B. 2001. Structure of human dipeptidyl peptidase I (cathepsin C): Exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 20: 6570-6582.
66. Turk V, Kos J, Turk B. 2004. Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell 5: 409-410.
67. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al. 2010. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250.
68. van Kempen LC, de Visser KE, Coussens LM. 2006. Inflammation, proteases and cancer. Eur J Cancer 42: 728-734.
69. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, et al. 2006. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66: 5242-5250.
70. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. 2001. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 276: 18551-18566.
71. Yuan F, Verhelst SH, Blum G, Coussens LM, Bogyo M. 2006. A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc 128: 5616-5617.